No abstract available.
Nocturnal Enuresis*

No abstract available.
Nocturnal Enuresis*

Nocturnal enuresis has been recognized as an adverse effect of clozapine treatment. We reported 3 chronic schizophrenic patients who had showed nocturnal enuresis following clozapine treatment. Oxybutynin hydrochloride on clozapine-induced enuresis was very effective in 3 patients. The dose in our patients was 5 to 10mg/day. This medication was well tolerated. It is suggested that oxybutynin hydrochloride is a effective therapeutic option in clozapine-induced nocturnal enuresis.
Clozapine* ; Enuresis ; Humans ; Nocturnal Enuresis* ; Schizophrenia

PURPOSE: The aim of this study, to investigate whether there is any association between enuresis in childhood and nocturnal polyuria syndrome (NPS) in adult life. METHODS: The study consisted of thirty five patients with nocturnal polyuria, and thirty five healthy people without nocturnal polyuria in adult life, were asked to assess their enuresis in childhood. RESULTS: There was a history of enuresis in childhood in 18 (51.42%) of 35 of men with nocturnal polyuria and in 4 (11.42%) of 35 without nocturnal polyuria. Enuresis in childhood was significantly more common in men with nocturnal polyuria than without nocturnal polyuria. The difference was significant (P<0.0001). The prevalence of enuresis in the nocturnal polyuria (51.42%) was more than two-fold higher than reported prevalence in general populations. CONCLUSIONS: The results of this study suggest that the history of enuresis in childhood seems to increase the risk of having NPS in adult life. This relationship should be taken into account in the evaluation of men with complaints from NPS in adult life and the possible common pathophysiology should be considered in the treatment planning.
Adult ; Child ; Enuresis ; Humans ; Male ; Nocturnal Enuresis ; Polyuria ; Prevalence

BACKGROUND: We examined the usefulness of urine osmolality, as a predictive factor in the treatment of monosymptomatic nocturnal enuresis (NE) with combination therapy of imipramine and desmopressin. METHODS: From May 2014 to April 2015, 59 monosymptomatic NE patients participated in this study. Early morning urine osmolality was measured at 1 week and 1 day before combination therapy of imipramine and desmopressin, and at 1 week and 2 weeks after therapy. The response to combination therapy was evaluated at 3 months after treatment. The mean period of combination therapy was 6.4+/-4.2 weeks. Therapeutic response was classified as complete (0-1 wet night/week), partial (over 50% reduction of night) and non-responders (less than 50% reduction of night). RESULTS: The cumulative rate of the complete and partial responders was 76.3%. Among the 3 groups, the statistically lowest value of pre-treatment urine osmolality was observed in the complete responder group (p<0.001). Urine osmolality increased in all groups after treatment, however, statistically the greatest difference between pre and post-treatment urine osmolality was observed in the complete responder group (p=0.024). No serious side effects were observed. CONCLUSION: Early morning urine osmolality and change of urine osmolality between pre and post-treatment have predictive values in the response to combined imipramine and desmopressin for treatment of monosymptomatic NE.
Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine* ; Nocturnal Enuresis* ; Osmolar Concentration*

PURPOSE: To investigate the correlation between functional bladder capacity, first morning urine osmolality, daytime voiding symptoms, and severity of nocturnal enuresis. MATERIALS AND METHODS: We assessed a total of 101 children with nocturnal enuresis (mean age, 7.7+/-2.3 years). Patients were divided into three groups according to the severity of enuresis: (1) one to six episodes per week (46 cases, 45.5%), (2) one episode every day (29 cases, 28.7%), and (3) multiple episodes every day (26 cases, 25.8%). Baseline parameters were obtained from frequency volume charts for 2 days, first morning urine osmolality, and a questionnaire for the presence of frequency, urgency, and daytime incontinence. RESULTS: The severity of enuresis increased with younger age (p=0.037) and reduced functional bladder capacity (p=0.007) and daytime symptoms of frequency and daytime incontinence (p=0.012, p=0.036). No statistical difference in urine osmolality or urgency was found among the three groups. Both reduced functional bladder capacity and low urine osmolality increased according to the severity of enuresis (p=0.012). CONCLUSIONS: In children with nocturnal enuresis, severity was increased by younger age, reduced functional bladder capacity, and the presence of daytime voiding symptoms of frequency and daytime incontinence. The incidence of small functional bladder capacity was increased in children with everyday wetting, and the incidences of both small functional bladder capacity and low urine osmolality were increased in children with everyday multiple wetting.
Child ; Enuresis ; Humans ; Incidence ; Nocturnal Enuresis ; Osmolar Concentration ; Urinary Bladder

The treatment of choice for primary nocturnal enuresis (PNE) in Korea remains imipramine which has proven to be effective in approximately 50 to 80%, but it is an antidepressant with toxic side effects and risk of overdose. Recently desmopressin (DDAVP, 1-desamino-8-Darginine-vasopressin) has been introduced for the treatment and its effect has been promising in many reports. To find the efficacy and safety of intranasal desmopressin, we evaluated the results of therapy in 48 enuretic children (34 boys and 14 girls). Mean age was 9.8 years (range 5-16). All the children were evaluated at least 3 months after the treatment with intranasal desmopressin. The overall response rate was 83.3%. The number of wet night per week before and after intranasal desmopressin treatment was 6.42 and 1.83 nights per week respectively. No side effects were observed. These data shows that the intranasal desmopressin therapy is effective and safe for the treatment of PNE.
Child ; Deamino Arginine Vasopressin* ; Enuresis ; Humans ; Imipramine ; Korea ; Nocturnal Enuresis*

Humans ; Magnetic Resonance Imaging ; Nocturnal Enuresis/diagnostic imaging*

PURPOSE: High arousal threshold, nocturnal polyuria and small nocturnal functional bladder capacity have been implicated as causes of nocturnal enuresis. The two medications most widely used for the treatment of enuresis are imipramine and desmopressin. This study evaluated the effects of imipramine and desmopressin on sleep arousal. MATERIALS AND METHODS: A total of 50 enuretic patients who had responded to medications from Mar 1999 to Dec 2001 were evaluated. The mean age was 7 years old(range, 5-16), and there were 40 boys and 10 girls. They were classified into three groups according to their medication: imipramine group(22 patients), desmopressin group(7) and the combination group (imipramine+desmopressin, 21 patients). The parents were asked to record whether the patients woke up or not for 100 consecutive nights. RESULTS: The mean number of nights/100 nights that the patients woke up in each group was 3.2+/-7.2 in the imipramine group, 1.2+/-0.7 in the desmopressin group and 5.0+/-7.6 in the combination group. CONCLUSIONS: The main mechanism of imipramine and desmopressin for the treatment of enuresis does not seem to be associated with sleep arousal.
Arousal* ; Deamino Arginine Vasopressin* ; Enuresis ; Female ; Humans ; Imipramine* ; Nocturnal Enuresis* ; Parents ; Polyuria ; Urinary Bladder

BACKGROUND: In recent years the treatment of primary nocturnal enuresis (PNE) with desmopressin (DDAVP) has been promising. The route of administration until now had been intranasal, but because the tablets were introduced for the treatment of diabetes insipidus they have also become available for the treatment of PNE. PURPOSES: To find the efficacy and safety of the treatment with desmopressin tablets in a group of children with monosymptomatic nocturnal enuresis. Materials and METHODS: The efficacy and safety of at least 3 months of treatment with oral desmopressin (1-deamino-8-D-arginine-vasopressin) (DDAVP tablets, Minirin) at doses of 200 to 600 ug. at bedtime were investigated in 50 children (ages 5 to 15 years) with monosymptomatic nocturnal enuresis. The efficacy of the drug was measured in reductions of the number of wet nights per week. RESULTS: The number of wet nights per week decreased from a mean of 6.1 to 2.0 (p<0.01). During the treatment period, 22 (44%) patients could be classified as good responders (0 to 1 wet night per week) and 15 (30%) as responders (over 50% reduction of wet night) and 13 (26%) as nonresponders (less than 50% reduction of wet night). No side effects we.e observed. CONCLUSION: Oral desmopressin has a clinically significant effect on patients with monosymptomatic nocturnal enuresis, and therapy is safe when administered as long-term treatment.
Child ; Deamino Arginine Vasopressin* ; Diabetes Insipidus ; Enuresis ; Humans ; Nocturnal Enuresis* ; Tablets*